Abstract:had single/multiple colorectal adenomas resected by endoscopy were enrolled in the study.The patients were randomly assigned to receive metformin (250 mg daily) or placebo by a stratified randomisation method.After 1 year of administration of metformin or placebo, colonoscopies were performed to evaluate the adenoma/polyp incidence and the number of adenoma/polyp as primary endpoint.Our analysis included all the participants who underwent random allocation according to the intention-to-treat principle.This trial is registered with UMIN000006254.Results: Between September 2011, and December 2014, 498 subjects who had had single/multiple colorectal adenomas resected by endoscopy were enrolled in the study.151 patients were randomly allocated; 79 were assigned to the metformin group and 72 were assigned to the placebo group.The incidences of total polyps and of adenomas in the metformin group was significantly lower than those in the placebo group: total polyps -metformin group 27/71, 38.0%, placebo group 35/62, 56.5%, p = 0.034, risk ratio 0.674 (95% CI 0.466-0.974);adenomas -metformin group 22/72, 30.6%, placebo group 32/62, p = 0.016, risk ratio 0.600 (95% CI 0.393-0.916).In the metformin group, the numbers of total polyps and adenomas were significantly lower than those in the placebo group (total polyps, p = 0.041; adenomas, p = 0.037).In the metformin group, the mean HOMA-IR value in non-recurrent patients after the 1-year treatment was significantly lower than the mean baseline value ( p = 0.029).In the placebo group, the mean baseline value of the HOMA-IR among recurrent patients was significantly higher than that in non-recurrent patients (p = 0.034).We observed no serious adverse events.Conclusion: The administration of low-dose metformin for 1 year to non-diabetic subjects was safe.Low-dose metformin reduced the incidence of metachronous adenomas or polyps after polypectomy.Metformin has a potential role in the chemoprevention of CRC.The HOMA-IR may act as a suitable predictor of responders to metformin in chemoprevention for CRC.However, further large-sample, long-term trials are needed to provide definitive conclusions.

The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma

Suppressive Effects of Metformin on Colorectal Adenoma Incidence and Malignant Progression

Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Metformin Use and Risk of Colorectal Adenoma after Polypectomy in Patients with Type 2 Diabetes Mellitus

Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression

Metformin Is Associated With Slightly Reduced Risk Of Colorectal Cancer And Moderate Survival Benefits In Diabetes Mellitus: A Meta-Analysis

Reduced Risk Of Colorectal Cancer With Metformin Therapy In Patients With Type 2 Diabetes A Meta-Analysis

Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis

Reduced Risk of Colorectal Cancer with Metformin Therapy in Patients with Type 2 Diabetes

Metformin administration in prevention of colorectal polyps in type 2 diabetes mellitus patients

Metformin may improve the outcome of patients with colorectal cancer and type 2 diabetes mellitus partly through effects on neutrophil extracellular traps

954 Proton-Pump Inhibitor (PPI) Versus Histamine-2 Receptor Antagonist (H2RA) for the Prevention of Recurrent Non-Variceal Upper Gastrointestinal Bleeding in High-Risk Users of Low-Dose Aspirin (ASA)

Effect Of Metformin On Cancer Risk And Treatment Outcome Of Prostate Cancer: A Meta-Analysis Of Epidemiological Observational Studies

Survival Benefits Of Metformin For Colorectal Cancer Patients With Diabetes: A Systematic Review And Meta-Analysis

Tumor-Suppressive Effect of Metformin via the Regulation of M2 Macrophages and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment of Colorectal Cancer

Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects

Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature

Impact of metformin use on the recurrence of hepatocellular carcinoma after initial liver resection in diabetic patients

Low‐dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin

Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer

Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis